美国 · 平台与数据 · Finviz
Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance
Few biotech earnings reports hinge on a single number the way this one does. Wall Street expects Zymeworks to post roughly $249.7 million in third-quarter revenue when it reports…
在 Finviz 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finviz.com)
